Lumexa Imaging Reports Strong Q4/FY25 Results, Significantly Reduces Net Loss, and Issues Positive 2026 Guidance
LMRI sits 42% above its 52-week low of $9.965.
Summary
Lumexa Imaging Holdings, Inc. announced strong preliminary unaudited financial results for Q4 and full year 2025, including significant revenue and Adjusted EBITDA growth and a substantial reduction in net loss, alongside positive 2026 guidance.
Key Events · Earnings and Guidance · LMRI
-
Strong Q4 and Full Year 2025 Performance
Lumexa Imaging reported preliminary unaudited consolidated revenues of at least $261 million for Q4 2025 (up 5.2% YoY) and at least $1.016 billion for full year 2025 (up 7.1% YoY). Adjusted EBITDA also saw strong growth, reaching at least $63 million for Q4 (up 17.3% YoY) and at least $229 million for the full year (up 14.0% YoY).
-
Significant Reduction in Net Loss
The company's preliminary unaudited net loss for full year 2025 is expected to be not larger than $43.8 million, a substantial decrease from $94.1 million in 2024, indicating improved profitability.
-
Positive 2026 Financial Guidance
Lumexa Imaging provided full year 2026 guidance, expecting consolidated revenues between $1.045 billion and $1.097 billion, and Adjusted EBITDA between $234 million and $242 million, signaling continued growth.
-
Strategic Growth Initiatives
The company continued its expansion strategy in 2025 by opening a record nine de novo centers and completing one acquisition, alongside progress in service line expansion, including PET imaging and an AI-powered Breast Arterial Calcification pilot.
Analysis · LMRI · Industrial Applications And Services
This filing reveals a robust financial performance for Lumexa Imaging, with significant year-over-year growth in both revenue and Adjusted EBITDA for Q4 and the full year 2025. The most impactful aspect is the substantial reduction in net loss for the full year, demonstrating improved operational efficiency and a clearer path to profitability. The 2026 guidance, while showing a slightly moderated growth rate for Adjusted EBITDA (partially due to public company costs), still projects continued expansion in both revenue and profitability. Investors should view these results as a strong indicator of the company's execution on its growth strategy, particularly its successful expansion through de novo centers and acquisitions, and its innovation in advanced imaging services. The preliminary nature of the results warrants attention to the final audited statements, but the current figures provide a positive outlook for the company's trajectory.
At the time of this filing, LMRI was trading at $14.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.97 to $19.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.